Answers are grounded in this paper and cite their sources.
Case report reveals treatment improved eosinophils and diabetes control in severe eosinophilic pneumonia patients, suggesting benralizumab's benefits.
Eosinophilic pneumonia (EP) often requires long‐term steroid treatment, which has adverse effects. We report the case of an 83‐year‐old male with minimal‐change nephrotic syndrome, refractory asthma and steroid‐induced diabetes who developed a severe steroid‐dependent EP relapse during steroid tapering. Considering his age, comorbidities and steroid dependency, treatment with benralizumab, an anti‐interleukin‐5 receptor antibody, was initiated. Benralizumab rapidly depleted eosinophils, leading to significant clinical and radiological improvements, allowing successful sustained tapering of prednisolone to 5 mg daily, and improving diabetes control without EP relapse. Benralizumab provides effective steroid‐sparing therapy for steroid‐dependent EP, particularly in complex patients.
No takes yet. Share an insight, caveat, or question.
ICHIKAWA et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: